Christopher Van Tuyl - 18 Dec 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role
Chief Legal Officer
Signature
/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl
Issuer symbol
IMVT
Transactions as of
18 Dec 2025
Net transactions value
-$290,943
Form type
4
Filing time
19 Dec 2025, 16:05:25 UTC
Previous filing
03 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Van Tuyl Christopher Chief Legal Officer C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK /s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl 19 Dec 2025 0001779707

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale $228,407 -8,529 -5.3% $26.78 152,214 18 Dec 2025 Direct F1, F2
transaction IMVT Common Stock Sale $62,536 -2,284 -1.5% $27.38 149,930 18 Dec 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 27,489 of these RSUs vested on December 16, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.23 - $27.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 - $27.52 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.